← Back to list
08.00.62r, Abatacept (Orencia®) for Injection for Intravenous Use
Act
by Oct 1, 2025
Effective date
Oct 1, 2025
Identified
Jun 19, 2026
Summary
Independence Blue Cross added ICD-10 diagnosis code M05.A (Abnormal rheumatoid factor and anti-citrullinated protein antibody with rheumatoid arthritis) to policy 08.00.62r for abatacept (Orencia) IV. This is a coding update that expands eligible diagnoses for coverage under existing medical necessity criteria. No changes to coverage criteria, billing codes, or prior authorization requirements.
Get alerts when payers change rules like this one
We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.
Get Independence Blue Cross alertsPolicy Monitoring is free. No card required.
What to do
by Oct 1, 2025 · 3 steps
01Billing team must update diagnosis code validation rules in the billing system to recognize M05.A as a covered indication for abatacept (Orencia) IV claims.
02Update internal coding reference materials and provider communication to reflect that M05.A qualifies for coverage when other medical necessity criteria are met.
03This is informational only—no workflow changes required as existing prior authorization processes and coverage criteria remain unchanged.
Codes mentioned
J0129M05.A
Original notice
08.00.62r, Abatacept (Orencia®) for Injection for Intravenous Use
medpolicy.ibx.com · Always check the source before changing claims.
Related changes
See all Independence Blue Cross changes →MA08.028k, Abatacept (Orencia®) for Injection for Intravenous UseLowEffective Oct 1, 2025 · Pharmacy08.00.62s, Abatacept (Orencia®) for Injection for Intravenous UseMediumEffective Oct 5, 2026 · PharmacyMA08.028l, Abatacept (Orencia®) for Injection for Intravenous UseMediumEffective Oct 5, 2026 · PharmacyMA08.070f, Golimumab (Simponi Aria®) Intravenous (IV) InjectionMediumEffective Oct 1, 2025 · PharmacyBrowse every Independence Blue Cross change in the policy list